Urokinase is mainly used in thrombolytic therapy for thromboembolic
diseases. Patients with acute generalized pulmonary embolism, coronary embolism
and myocardial infarction within 6-12 hours of chest pain, acute cerebrovascular
embolism with symptoms shorter than 3-6 hours, retinal artery embolism and other
peripheral artery embolism with severe symptoms of ilio-femoral vein thrombosis.
It is also used to prevent thrombosis after artificial heart valve operation,
keep vascular intubation and drainage tube of thoracic cavity and pericardium
patency, etc. The efficacy of thrombolysis was maintained by subsequent
anticoagulation with heparin.
Urokinase is an enzymatic thrombolytic drug, which can activate plasminogen
to plasminolytic enzyme in vivo, thus hydrolyzing fibrin to dissolve freshly
formed thrombus. For acute myocardial infarction, acute cerebral thrombosis and
cerebrovascular embolism, arteriovenous thrombosis around limbs, arteriovenous
thrombosis in the central retina and other fresh thrombosis occlusive diseases.
Urokinase has no obvious effect on old thrombus. It is also suitable for the
treatment of cerebral thrombosis, peripheral vascular embolism, central retinal
vascular embolism, acute myocardial infarction and other fresh thromboembolic
diseases, as well as renal transplantation, plastic surgery and other
thrombosis, and has a good effect.
Above is the relevant content summarized by Kang Yuan's editor. If you want
to know more, please follow us. We will update you regularly about Human
Chorionic Gonadotropin, Human Menopausal Gonadotropin supplier, Urofollitropin
price, Urokinase manufacturer, Hormone API manufacturer.